Laurent Peyrin-Biroulet
Overview
Explore the profile of Laurent Peyrin-Biroulet including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
970
Citations
24829
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dziegielewski C, Yuan Y, Ma C, Boland B, Chang J, Syal G, et al.
Am J Gastroenterol
. 2025 Mar;
PMID: 40071763
Background And Aims: We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing interleukin (IL)-23p19 antagonists with ustekinumab, stratified by prior biologic exposure, in patients with moderate-to-severe...
2.
Richard N, Amiot A, Seksik P, Altwegg R, Laharie D, Vuitton L, et al.
Aliment Pharmacol Ther
. 2025 Mar;
PMID: 40038887
Background: Real-world effectiveness and safety of upadacitinib in patients with Crohn's disease (CD) remain unclear. Aims: This study aimed to evaluate the effectiveness and safety of upadacitinib in a real-world...
3.
Mariette X, Borchmann S, Aspeslagh S, Szekanecz Z, Charles-Schoeman C, Schreiber S, et al.
RMD Open
. 2025 Mar;
11(1).
PMID: 40037922
Objectives: Long-term safety is fundamental for treatment decision-making. This integrated analysis of filgotinib clinical trials in rheumatoid arthritis (RA) and ulcerative colitis (UC) assessed adverse events of interest (AEI): major...
4.
Altieri G, Zilli A, Parigi T, Allocca M, Furfaro F, Fiorino G, et al.
Biomolecules
. 2025 Feb;
15(2).
PMID: 40001525
Inflammatory bowel diseases (IBDs), including ulcerative colitis (UC) and Crohn's disease (CD), are chronic and complex autoimmune conditions. Despite the advancements in biologics and small molecules, the therapeutic ceiling persists,...
5.
DAmico F, Bencardino S, Goncalves A, Allocca M, Furfaro F, Zilli A, et al.
United European Gastroenterol J
. 2025 Feb;
PMID: 39967304
Biologic therapies have revolutionized Crohn's disease (CD) management, but their high costs pose a significant barrier to access. Biosimilars can provide increased access to treatment because of significant cost-savings. Ustekinumab...
6.
Vieujean S, Jairath V, Peyrin-Biroulet L, Dubinsky M, Iacucci M, Magro F, et al.
Nat Rev Gastroenterol Hepatol
. 2025 Feb;
PMID: 39930068
No abstract available.
7.
Disease-modifying anti-inflammatory drugs (DMAIDs): shaping the future of inflammatory bowel disease
Honap S, Peyrin-Biroulet L
J Crohns Colitis
. 2025 Feb;
19(3).
PMID: 39921380
No abstract available.
8.
Temido M, Honap S, Jairath V, Vermeire S, Danese S, Portela F, et al.
Lancet Gastroenterol Hepatol
. 2025 Feb;
PMID: 39919770
Several therapeutic advances have been achieved over the past two decades for inflammatory bowel disease (IBD). The expanding therapeutic armamentarium and the increasingly ambitious treatment targets have led to an...
9.
Dal Buono A, Faita F, Armuzzi A, Jairath V, Peyrin-Biroulet L, Danese S, et al.
J Crohns Colitis
. 2025 Feb;
19(2).
PMID: 39901740
Background And Aims: Cross-sectional imaging techniques, including intestinal ultrasonography (IUS), computed tomography enterography (CTE), magnetic resonance enterography (MRE), are increasingly used for the evaluation of inflammatory bowel diseases (IBD). We...
10.
Afzali A, Regueiro M, Yarur A, Zabana Y, Ng S, Menon S, et al.
United European Gastroenterol J
. 2025 Feb;
PMID: 39891572
Background: Etrasimod is an oral, once-daily (q.d.), selective sphingosine 1-phosphate (S1P) receptor modulator for the treatment of moderately to severely active ulcerative colitis (UC). Unlike the S1P receptor modulator ozanimod,...